Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Treatment Resistent Cancers

Treatment Resistent Cancers

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease.

Current oncology (Toronto, Ont.)·2020

Same author

Prognostic Importance of Pathological Fractures in Osteosarcomas.

Irish medical journal·2020

Same author

Osteosarcoma and second malignant neoplasms: a case series.

Irish journal of medical science·2019

Same author

Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials.

Current oncology (Toronto, Ont.)·2018

Same author

Is chemotherapy always required for cancer in pregnancy? An observational study.

Irish journal of medical science·2017

Same author

The impact of contemporary multidisciplinary meetings on workload at a tertiary level hospital.

Irish journal of medical science·2016

Same journal

Unlocking the potential of electronic health records for research purposes.

Irish medical journal·2026

Same journal

ICU Handover: A Persistent Vulnerability in Critical Care Settings.

Irish medical journal·2026

Same journal

The Sugar-Sweetened Beverage Tax (Sugar Tax): Innovation and Stasis.

Irish medical journal·2026

Same journal

Gastrointestinal trichobezoars presenting as abdominal pain and obstruction - Rapunzel syndrome.

Irish medical journal·2026

Same journal

When Sepsis Kills: A Fatal Cascade of Invasive Group A Streptococcal Sepsis.

Irish medical journal·2026

Same journal

Fulminant Thrombotic Thrombocytopenic Purpura presenting through the FAST Stroke Pathway.

Irish medical journal·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 14, 2026

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Published on: September 9, 2020

Osteosarcoma in a Patient Receiving Long-Term TNF Inhibitor Therapy.

J Greene¹, G M O'Kane¹, D N Carney¹

¹Medical Oncology Department, Mater Misericordiae University Hospital, Dublin 7.

Irish Medical Journal

|September 30, 2016

Summary

This summary is machine-generated.

This case study highlights a potential increased malignancy risk in Crohn's disease patients using adalimumab (a tumor necrosis factor inhibitor). Early cessation of therapy and combined treatment approaches are recommended.

More Related Videos

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study

Published on: March 22, 2024

Related Experiment Videos

Last Updated: Mar 14, 2026

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Published on: September 9, 2020

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study

Published on: March 22, 2024

Area of Science:

Oncology
Gastroenterology
Immunology

Background:

Patients with inflammatory bowel disease (IBD) exhibit a higher incidence of malignancy.
Immunosuppressive drugs, including tumor necrosis factor (TNF) inhibitors, may further elevate cancer risk in IBD patients.

Purpose of the Study:

To report a case of high-grade osteosarcoma in a Crohn's disease patient undergoing TNF inhibitor therapy.
To discuss the potential association between adalimumab use and increased malignancy risk.

Main Methods:

Clinical and pathological findings of a rare osteosarcoma case presentation.
Review of existing literature on TNF inhibitors and malignancy risk in IBD.

Main Results:

A 32-year-old female developed a high-grade osteosarcoma in her right knee after six years of adalimumab maintenance therapy for Crohn's disease.
The case suggests a possible link between long-term adalimumab use and the development of malignancy.

Conclusions:

TNF inhibitor therapy, such as adalimumab, may be associated with an increased risk of malignancy in IBD patients.
Discontinuation of TNF inhibitors and multimodal treatment (chemotherapy and surgery) are suggested for patients developing cancer.
Further research is needed to clarify the role and safety of TNF inhibitors in IBD patients post-cancer diagnosis.